

US009097713B2

# (12) United States Patent

Dye et al.

(10) Patent No.: US 9,097,713 B2

(45) **Date of Patent:** 

Aug. 4, 2015

## (54) MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS

(75) Inventors: John M. Dye, Frederick, MD (US); Ana

I. Kuehne, Frederick, MD (US); Shawn

B. Guest, Frederick, MD (US)

(73) Assignee: THE UNITED STATES OF

AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY ON BEHALF OF USAMRMC,

Washington, DC (US)

(\*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 203 days.

(21) Appl. No.: 13/393,622

(22) PCT Filed: Sep. 1, 2010

(86) PCT No.: **PCT/US2010/047586** 

§ 371 (c)(1),

(2), (4) Date: Mar. 1, 2012

(87) PCT Pub. No.: WO2011/071574

PCT Pub. Date: Jun. 16, 2011

## (65) **Prior Publication Data**

US 2012/0164153 A1 Jun. 28, 2012

## Related U.S. Application Data

- (60) Provisional application No. 61/239,166, filed on Sep. 2, 2009, provisional application No. 61/290,725, filed on Dec. 29, 2009.
- (51) **Int. Cl.**

 G01N 33/569
 (2006.01)

 C07K 16/10
 (2006.01)

 A61K 39/00
 (2006.01)

(52) U.S. Cl.

CPC ............ *G01N 33/56983* (2013.01); *C07K 16/10* (2013.01); *A61K 2039/505* (2013.01); *C07K 2317/34* (2013.01); *C07K 2317/76* (2013.01); *C12N 2760/14111* (2013.01); *G01N 2333/08* (2013.01)

(58) Field of Classification Search

See application file for complete search history.

## (56) References Cited

#### U.S. PATENT DOCUMENTS

6,630,144	D 1	10/2003	Hart et al.
6,875,433	B2	4/2005	Hart et al.
6,984,504	B2	1/2006	Hart et al.
7,335,356	B2	2/2008	Hart et al.
2002/0164582	A1	11/2002	Hart et al.
2003/0224015	A1	12/2003	Hart et al.
2004/0053865	A1	3/2004	Hart et al.
2004/0146859	A1	7/2004	Hart et al.

#### FOREIGN PATENT DOCUMENTS

WO 96/37616 11/1996

#### OTHER PUBLICATIONS

TheiBen, G., 2002, Secret life of genes, Nature 415:741.\*

Choi, K. H., et al., 2004, Design, expression, and purification of a Flaviviridae polymerase using a high-throughput approach to faciliate crystal structure determination, Prot. Sci. 13:2685-2692.\*

Li, Yi., et al., 1996, The I binding specificity of human VH4-34 (VH4-21) encoded by antibodies is determined by both VH framework region 1 and complementarity determining region 3, J. Mol. Biol. 256:577-589.\*

Winkler, K., et al., 2000, Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody, J. Immunol. 165:4505-4514.\*

S.V.S. Kashmiri et al., "Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49," Critical Reviews in Oncology/Hematology, vol. 38, 2001, pp. 3-16. J. Pettitt et al., "Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail," Science Translational Medicine, vol. 5, Issue 199 199ra113, Aug. 21, 2013, pp. 1-6.

J. Dye et al., "Sudan Ebolavirus Specific Murine Monoclonal Antibodies," presented at 3rd Annual International Filovirus Symposium, Gabon, Africa (Mar. 26-28, 2008).

Ana Kuehne et al., "Sudan Ebolavirus Specific Murine Monoclonal Antibodies," presented at ASM Biodefense and Emerging Diseases Research Meeting, Baltimore, MD (Feb. 22-25, 2009).

International Search Report issued on Aug. 18, 2011 in International Application No. PCT/US2010/047586 filed Sep. 1, 2010.

## \* cited by examiner

Primary Examiner — Jeffrey Parkin (74) Attorney, Agent, or Firm — Drinker Biddle & Reath LLP

#### (57) ABSTRACT

We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo.

## 8 Claims, 23 Drawing Sheets